Centiva Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Centiva Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-25,496	Closed	-$17K	–	1610
2020 Q4	$17K	Buy	+25,496	New	+$54.3K	﹤0.01%	884
2020 Q3	–	Sell	-25,496	Closed	-$92K	–	954
2020 Q2	$92K	Buy	+25,496	New	+$92K	0.01%	586
2020 Q1	–	Sell	-100,896	Closed	-$304K	–	1011
2019 Q4	$304K	Buy	+100,896	New	+$262K	0.01%	558

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Centiva Capital's BMY.RT Position: Q1 2021 in Review

Centiva Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 25,496 shares — an estimated $17K sold.

Centiva Capital first reported a position in BMY.RT in Q4 2019 and held it in 3 quarters. The position peaked at $304K in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Centiva Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Centiva Capital sold 25,496 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $17K.
Centiva Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 3 quarters.
Centiva Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $304K in Q4 2019.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Centiva Capital's 13F filing for Q1 2021, filed 17 May 2021.